Nurix Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.nurixtx.com

Moat Score

Market Cap $1.35B
PE -8
Debt $NaN
Cash $99.95M
EV $NaN
FCF -$106.90M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$176.98M
EBIT	-$176.71M
ROE	-47%
ROA	-34%
FCF	-$106.90M
Equity	$376.86M
Growth Stability	1
PE	-7.65
PB	3.59
P/FCF	-12.67
P/S	24.01
Price/Cash	0.07
Net Margins	-327%
Op. Margins	-313%
Sales Growth YoY	-32%
Sales Growth QoQ	4%
Sales CAGR	34%
Equity CAGR	-5%
Earnings Growth YoY	32%

Earnings Growth QoQ	10%
Sales CAGR 5Y	36%
Equity CAGR 5Y	-5%
Earnings CAGR 3Y	38%
Sales CAGR 3Y	38%
Equity CAGR 3Y	-5%
Market Cap	$1.35B
Revenue	$56.42M
Assets	$513.60M
Cash	$99.95M
Shares Outstanding	63.38M
Moat Score	1%
Working Capital	369.75M
Current Ratio	5.28
Shares Growth 3y	11%
Equity Growth QoQ	2%
Equity Growth YoY	61%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

SEC Filings

Direct access to Nurix Therapeutics, Inc. (NRIX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Aug 31
- 10-Q May 31
- 10-Q Feb 29
2023
- 10-K Nov 30
- 10-Q Aug 31
- 10-Q May 31
- 10-Q Feb 28
2022
- 10-K Nov 30
- 10-Q Aug 31
- 10-Q May 31
- 10-Q Feb 28

Sector Comparison

How does Nurix Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Nurix Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Nurix Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Nurix Therapeutics, Inc..

Years

Calculation mode

= -$1.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$107M	-$107M	-$107M	-$107M	-$107M	-$107M	-$107M	-$107M	-$107M	-$107M	-$107M	-$1.1B
DCF		-$97M	-$88M	-$80M	-$73M	-$66M	-$60M	-$55M	-$50M	-$45M	-$41M	-$412M
Value	-$1.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	11/2019	11/2020	11/2021	11/2022	11/2023	TTM
Net Margins	-70%	-243%	-394%	-467%	-187%	-327%
ROA	-	-16%	-25%	-43%	-40%	-34%
ROE	-	-15%	-34%	-59%	-72%	-47%

Bad Net Margins (-327.2%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	11/2019	11/2020	11/2021	11/2022	11/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	11/2019	11/2020	11/2021	11/2022	11/2023	CAGR 5Y
Revenue YoY growth	-	-43%	67%	30%	99%	36%
Earnings YoY growth	-	99%	171%	54%	-20%	-
Equity YoY growth	-	-603%	18%	-11%	-34%	-5%
FCF YoY growth	-	341%	2K%	91%	-48%	-